Sientra selling implants again but staff cut as losses mount
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Stellar Biotechnologies revenues nearly doubled in first quarter
Stellar Biotechnologies revenues nearly doubled but so did the company’s losses during the first quarter, the Port Hueneme biotech company reported May 9. Stellar Biotechnologies makes a protein for immunotherapy treatments using a unique sea snail only found off the coastal shores of a small part of California. The company’s revenues increased from $187,627 during Read More →
Read More →LTC Properties beat first quarter revenue estimates
Westlake Village-based LTC Properties beat analyst projections of revenue and funds from operations in its 2016 first quarter earnings report. The publicly traded real estate and investment trust earned $31.88 million in revenue, up from $26.68 million in the first quarter of 2015, surpassing analyst projections by $820,000. LTC Properties funds from operations per common share Read More →
Read More →UCLA Health Services buys medical office building in Thousand Oaks
The UCLA Board of Regents has paid more than $10 million to buy a medical office building from TR Funding, LLC, of Westlake Village that houses UCLA Health Services at 100 Moody Court in Thousand Oaks. The 23,614-square-foot building has been home to a UCLA Health medical clinic since 2013, offering primary and specialty care Read More →
Read More →Amgen exceeds Wall Street expectations for first quarter earnings
Amgen blew away Wall Street expectations and raised its 2016 guidance when it released first quarter earnings April 28. The Thousand Oaks biotech giant had profits of $2.2 billion, up from $1.91 billion during the same quarter last year. Revenues of $5.53 billion were also up from $5 billion in 2015 and surpassed analyst estimates Read More →
Read More →Acelot’s software finds new drug combinations
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →